ACP
CNTA

Acuta Capital Partners’s Centessa Pharmaceuticals CNTA Stock Holding History

Acuta Capital Partners’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-38,138
Closed -$304K – 38
2023
Q4 		$304K Sell
38,138
-285,211
-88% -$1.91M 0.17% 36
2023
Q3 		$2.09M Buy
+323,349
New +$2.21M 1.4% 24

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Acuta Capital Partners's CNTA Position: Q1 2024 in Review

Acuta Capital Partners sold out of Centessa Pharmaceuticals (CNTA) in Q1 2024, closing a stake of 38,138 shares — an estimated $304K sold.

Acuta Capital Partners first reported a position in CNTA in Q3 2023 and held it in 2 quarters. The position peaked at $2.09M in Q3 2023. 69 funds tracked by Wall St. Rank hold CNTA as of Q1 2024.

  • Acuta Capital Partners reported no remaining Centessa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 38,138 Centessa Pharmaceuticals shares in Q1 2024, an estimated $304K.
  • Acuta Capital Partners first reported a position in Centessa Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Acuta Capital Partners's Centessa Pharmaceuticals position peaked at $2.09M in Q3 2023.
  • 69 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2024.

Based on Acuta Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.